Abstract
Prostate cancer in men is similar to breast cancer in women; both cancers rank first, respectively, in incidence and are normally responsive to radiation therapy. In addition, advances in mammography help detect earlier breast cancers, and the development and refinement of prostatic specific antigen (PSA) has resulted in early detection of low-stage localized prostate cancers. This has generated debate over the proper management of localized prostate cancer. While there have not been any controlled, prospective, randomized trials of sufficient power to compare the various local therapies, based on the current available data, the three commonly used local modalities, surgery, and external beam radiation therapy and brachytherapy (radioactive seed implant), have similar efficacy controlling the disease up to 10 years in many patients. Technological advances in treatment delivery and planning have improved the treatment of prostate cancer with external-beam radiotherapy using three-dimensional conformal radiotherapy (3DCRT), ultrasound-guided transperineal implant, or intensity-modulated radiotherapy (IMRT), as well as proton or neutron beam based therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 239-257 |
| Number of pages | 19 |
| Journal | Urologic Oncology |
| Volume | 7 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2002 |
Fingerprint
Keywords
- Brachytherapy
- External beam radiation therapy
- Intensity-modulated radiotherapy
- Prostate cancer
- PSA
- Three-dimensional conformal radiotherapy
- Ultrasound-guided transperineal implant
ASJC Scopus subject areas
- Oncology
- Urology
Cite this
Primary radiation therapy for localized prostate cancer. / Eng, Tony Y.; Thomas, Charles R.; Herman, Terrence S.
In: Urologic Oncology, Vol. 7, No. 6, 11.2002, p. 239-257.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Primary radiation therapy for localized prostate cancer
AU - Eng, Tony Y.
AU - Thomas, Charles R.
AU - Herman, Terrence S.
PY - 2002/11
Y1 - 2002/11
N2 - Prostate cancer in men is similar to breast cancer in women; both cancers rank first, respectively, in incidence and are normally responsive to radiation therapy. In addition, advances in mammography help detect earlier breast cancers, and the development and refinement of prostatic specific antigen (PSA) has resulted in early detection of low-stage localized prostate cancers. This has generated debate over the proper management of localized prostate cancer. While there have not been any controlled, prospective, randomized trials of sufficient power to compare the various local therapies, based on the current available data, the three commonly used local modalities, surgery, and external beam radiation therapy and brachytherapy (radioactive seed implant), have similar efficacy controlling the disease up to 10 years in many patients. Technological advances in treatment delivery and planning have improved the treatment of prostate cancer with external-beam radiotherapy using three-dimensional conformal radiotherapy (3DCRT), ultrasound-guided transperineal implant, or intensity-modulated radiotherapy (IMRT), as well as proton or neutron beam based therapies.
AB - Prostate cancer in men is similar to breast cancer in women; both cancers rank first, respectively, in incidence and are normally responsive to radiation therapy. In addition, advances in mammography help detect earlier breast cancers, and the development and refinement of prostatic specific antigen (PSA) has resulted in early detection of low-stage localized prostate cancers. This has generated debate over the proper management of localized prostate cancer. While there have not been any controlled, prospective, randomized trials of sufficient power to compare the various local therapies, based on the current available data, the three commonly used local modalities, surgery, and external beam radiation therapy and brachytherapy (radioactive seed implant), have similar efficacy controlling the disease up to 10 years in many patients. Technological advances in treatment delivery and planning have improved the treatment of prostate cancer with external-beam radiotherapy using three-dimensional conformal radiotherapy (3DCRT), ultrasound-guided transperineal implant, or intensity-modulated radiotherapy (IMRT), as well as proton or neutron beam based therapies.
KW - Brachytherapy
KW - External beam radiation therapy
KW - Intensity-modulated radiotherapy
KW - Prostate cancer
KW - PSA
KW - Three-dimensional conformal radiotherapy
KW - Ultrasound-guided transperineal implant
UR - http://www.scopus.com/inward/record.url?scp=0036868271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036868271&partnerID=8YFLogxK
U2 - 10.1016/S1078-1439(02)00198-9
DO - 10.1016/S1078-1439(02)00198-9
M3 - Article
C2 - 12504845
AN - SCOPUS:0036868271
VL - 7
SP - 239
EP - 257
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
SN - 1078-1439
IS - 6
ER -